Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 9Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Neoplasms 2Lung Neoplasms 2Endometrial Neoplasms 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × sintilimab × 1 year × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
150 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

First Affiliated Hospital of Guangxi Medical University

Phase 3 Recruiting
266 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡